--- canonical_url: https://www.stockexpertai.com/zh/earnings/cvs last_updated: 2026-07-07T06:15:59.437Z --- # CVS Health Corp. (CVS) Q4 FY2026 财报预览 > 此内容由 FMP 实时数据 + Q1 FY2026 财报电话会议记录自动生成。生成时间：2026-07-07T06:15:58.634Z。本工具为教育目的，不构成投资建议。 --- ## 快速摘要 | 字段 | 值 | 来源 | |---|---|---| | 价格 | $102.08 (▼ -2.52%) | fmp:quote | | 市值 | $130.2B | fmp:profile | | 52周区间 | $58.50 – $106.15 | fmp:quote | | 财报 | 周四 30 7月 | fmp:earnings-history | | EPS 预期 | $1.86 (+3% YoY) | fmp:earnings-estimate | | 营收预期 | $100.2B | fmp:earnings-estimate | | 超预期连胜 | 6/4 | fmp:earnings-history | | 评级 | B+ (overall 3/5) | fmp:ratings | | 分析师中位数目标价 | $106 (+3.8% upside) | fmp:price-target-consensus | | MoonshotScore | 46/100 | derived | | Council | 2/6 bullish | derived | | 芒格结论 | 合理估值 | derived | ## CVS Health Corp. — Q4 FY2026 预期 Q4 季度共识：营收 $100.2B^{[FMP est]}，EPS $1.86^{[FMP est]}。连续 6 个季度超出预期^{[FMP earnings]}。 ## 快速概览 **得分：** B+ · **立场：** HOLD · **Council：** 2/6 · **Moonshot：** 46 = MoonshotScore 46^{[MoonshotScore]} + Council 2/6^[Council]。Form 4: 0 笔交易^{[FMP Form 4]}。 ## 观察列表 (5个指标) ### 1. Fy26 Eps Guidance Increase CVS Health在第一季度表现强劲后，将其2026财年全年调整后每股收益（EPS）指引上调至7.30美元至7.50美元的范围。 > "我们第一季度的强劲表现使我们有信心将2026财年全年调整后每股收益指引从之前的7美元至7.20美元的范围上调至7.30美元至7.50美元的范围。" > — David Joyner, Chair and Chief Executive Officer, Expectation / Guide · Q1 FY2026 ### 2. Cash Flow Leverage CVS Health在第一季度产生了42亿美元的运营现金流，并将其杠杆率改善至3.84倍，显示出强劲的财务状况和向股东回馈价值的能力。 > "在第一季度，我们产生了约42亿美元的运营现金流，并通过季度股息向股东返还了近8.5亿美元。我们第一季度末的杠杆率改善至3.84倍。" > — Brian Newman, Chief Financial Officer, Investor Focus · Q1 FY2026 ### 3. Aetna Margin Recovery Aetna在第一季度实现了超过10亿美元的调整后营业收入同比增长，这得益于其利润恢复计划的成功执行。 > "我们在Aetna实现了超过10亿美元的调整后营业收入（AOI）同比增长。" > — Brian Newman, Chief Financial Officer, Risk Indicator · Q1 FY2026 ### 4. Prior Authorization Efficiency Aetna在运营效率方面处于领先地位，其医疗服务中需要事先授权的比例在行业中最低，超过95%的符合条件的事先授权在24小时内获得批准，其中超过80%是实时批准的。 > "Aetna在行业中拥有最少需要事先授权的医疗服务。我们专注于将技术嵌入到每个业务中，这使我们能够在24小时内批准超过95%的符合条件的事先授权，其中超过80%是实时批准的。" > — David Joyner, Chair and Chief Executive Officer, Investor Focus · Q1 FY2026 ### 5. Biosimilar Adoption Strategy CVS Health将从2026年7月1日起，将其商业处方集中的品牌STELARA替换为低成本生物仿制药，旨在复制HUMIRA超过90%的患者转换成功率。 > "我们最近宣布，自2026年7月1日起，我们将把品牌STELARA从我们的商业模板处方集中移除，并替换为低成本、有效的生物仿制药。我们将采用与HUMIRA相同的成熟策略，该策略使我们成为唯一能够显著改变市场份额的公司，转换了超过90%的符合条件的患者。" > — David Joyner, Chair and Chief Executive Officer, Investor Focus · Q1 FY2026 ## MoonshotScore 支柱 | 支柱 | 得分 | 水平 | 证据 | |---|---|---|---| | 营收增长 | 1.0 | weak | Q1 vs Q2: 增长放缓 (+%1.5，低于阈值) | | 毛利率 | 2.0 | weak | Q1: 低毛利率 (%15.6，资本密集型或大宗商品) | | 经营杠杆 | 0.0 | weak | 营业利润率疲弱 (%4.7，承压) | | 现金流储备 | 10.0 | strong | FCF 非常强劲 ($3.4B，是资本支出的 4.0 倍以上) | | 研发投入强度 | 3.0 | weak | 低研发投资 (%0.0，创新薄弱) | | 价格动能 | 7.0 | strong | RSI 59.1 动能积极，50日均线之上 | | 新闻情绪 | 9.0 | strong | 强烈买入共识 (86%) | **公式:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7视角) | 名称 | 立场 | 背景 | |---|---|---| | Ray Dalio | bull | 宏观 · 目标上涨空间 +3.8% | | Ken Griffin | bull | 资金流 · 50日均线之上 | | Jim Simons | neutral | 量化 · RSI 59 | | Klarman | neutral | 价值 · 目标上涨空间 +3.8% | | Buffett | neutral | 质量 · ROE 评分 3/5 | | Munger | neutral | 估值 · 目标上涨空间 +3.8% | **公式:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## 芒格视角 - **结论:** 合理估值 - **财务健康:** Moderate - **安全边际:** Weak - **利息覆盖率:** Adequate - **ROIC vs WACC:** Tight **公式:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## 技术水平 - **RSI(14):** 59.1 — yükselişte nötr — overbought sınırının altında, momentum pozitif - **50日均线:** $94 — hisse %8.7 üstünde — kısa vadeli destek - **200日均线:** $82 — hisse %24.9 üstünde — uzun vadeli destek - **成交量 (10日):** -21% ## 历史表现 (4个季度) | 季度 | 实际 EPS | 预期 EPS | 结果 | 反应 | |---|---|---|---|---| | Q2 FY25 | $1.81 | $1.46 | BEAT | +0.6% | | Q3 FY25 | $1.60 | $1.37 | BEAT | -4.9% | | Q4 FY25 | $1.09 | $1.00 | BEAT | +1.9% | | Q1 FY26 | $2.57 | $2.18 | +17.9% EPS | +0.6% | Q1 (2026年5月7日): EPS $2.57 vs 预期 $2.18^[FMP]，超出 +%17.9。D+1 走势：+0.6%^{[FMP D+1]}。尽管超出预期，但股价下跌 — 市场对指引而非数据做出反应。 ## 3种情景 ### 情景 A · 超预期 **Q4 EPS > $1.86 + 资本支出纪律** 阈值：EPS > $1.86^{[FMP est]}。目标：突破中位数目标价 $106^{[FMP target]}；高目标价 $115^[FMP] 为上限。 ### 情景 B · 符合预期 **EPS ≈ $1.86 + CapEx < $849.0M** 阈值：EPS ≈ $1.86^{[FMP est]}，Q4 资本支出 < $849.0M^[FMP]。目标：在当前价 $102^[FMP] 与中位数目标价 $106^[FMP] 区间内盘整。 ### 情景 C · 未达预期 **EPS < $1.80 或 CapEx ≥ $849.0M** 阈值：EPS < $1.80^{[FMP est×0.97]}。目标：当前价 $102 低于 200日均线 $82^[FMP]，若持续拒绝，则激活 $69^[derived] 支撑位。 ## 风险提示 ### {{segment}} 低于阈值 Q1 季度：EPS $2.57 vs 预期 $2.18^[FMP]，超出预期，股价 D+1 +0.6%^[FMP]。 ### 对 OpenAI 的依赖 Q1 财报电话会议中未披露 RPO/积压集中度。 ### 内幕交易 Form 4 数据已在表格中标记 — 本页面不为此股票生成假设。 | 高管 | 操作 | 金额 | 日期 | |---|---|---|---| **净额:** — (0 笔交易 · 0 笔卖出 · 0 笔买入) · Q1 FY26 ### 资本支出冲击 Q1 季度资本支出 $849.0M^{[FMP cashflow]}。 Q1 营业利润率 %4.7^{[FMP op margin]} — Q4 的这一水平对资本支出修订风险敏感。 ## 华尔街共识 - **中位数目标价:** $106 (+3.8% upside vs current $102) - **高 / 低:** $115 / $90 - **买入 / 持有 / 卖出:** 24 / 4 / 0 - **分析师数量:** 14 (上一季度), 81 历史总数 ## 额外财报电话会议洞察 ### 1. fy26_eps_guidance_increase **主张:** CVS Health raised its full year 2026 adjusted earnings per share (EPS) guidance to a range of $7.30 to $7.50 following strong first-quarter performance. **证据 (会议记录):** "Our strong first quarter performance gave us the confidence to increase our full year 2026 adjusted earnings per share guidance to a range of $7.30 to $7.50, up from the previous range of $7 to $7.20." **数据:** $7.30, $7.50, $7, $7.20 ### 2. aetna_margin_recovery **主张:** Aetna achieved over $1 billion of year-over-year adjusted operating income improvement in the first quarter due to successful execution of its margin recovery plans. **证据 (会议记录):** "We drove over $1 billion of year-over-year AOI improvement at Aetna." **数据:** $1 billion ### 3. biosimilar_adoption_strategy **主张:** CVS Health will exclude branded STELARA from its commercial formularies starting July 1, 2026, replacing it with low-cost biosimilars, aiming to replicate the over 90% patient conversion success achieved with HUMIRA. **证据 (会议记录):** "We recently announced that on July 1, 2026, we will exclude branded STELARA from our commercial template formularies to be replaced with the low-cost, effective biosimilars. We'll use the same proven playbook that allowed us to be the only ones to meaningfully move share with HUMIRA, converting over 90% of eligible patients." **数据:** July 1, 2026, 90% ### 4. prior_authorization_efficiency **主张:** Aetna leads in operational efficiency by having the fewest medical services subject to prior authorization in the industry, approving over 95% of eligible prior authorizations within 24 hours, with over 80% approved in real time. **证据 (会议记录):** "Aetna has the fewest medical services subject to prior authorization in the industry. Our focus on embedding technology within each of our businesses has enabled us to approve more than 95% of the eligible prior authorizations within 24 hours, with over 80% being approved in real time." **数据:** 95%, 24 hours, 80% ### 5. health100_ai_platform **主张:** CVS Health will launch Health100 later this year, an AI-native technology and service platform designed to seamlessly connect any payer, PBM, pharmacy, or provider. **证据 (会议记录):** "Later this year, we will be launching Health100, an AI native, state-of-the-art technology and service platform that allows for any payer, PBM, pharmacy or provider to seamlessly connect." **数据:** — ### 6. cash_flow_leverage **主张:** CVS Health generated $4.2 billion in cash flow from operations in the first quarter and improved its leverage ratio to 3.84x, demonstrating strong financial health and capacity to return value to shareholders. **证据 (会议记录):** "In the first quarter, we generated cash flows from operations of approximately $4.2 billion and returned nearly $850 million to our shareholders through our quarterly dividend. Our leverage ratio at the end of the first quarter improved to 3.84x." **数据:** $4.2 billion, $850 million, 3.84x --- *数据来源：FMP (实时查询，2026-07-07)，Q1 FY2026 财报电话会议记录 (由 Gemini 2.0 Flash 翻译成中文)。本工具为教育目的，不构成投资建议。*